CD146号
川地31
血管性血友病因子
流式细胞术
生物
分子生物学
内皮
实时聚合酶链反应
免疫学
男科
血小板
川地34
医学
内分泌学
免疫组织化学
细胞生物学
生物化学
基因
干细胞
作者
Michiel Strijbos,Brigitte van Krimpen,Reno Debets,Jaco Kraan,Stefan Sleijfer,Jan W. Gratama,C B Lamers
出处
期刊:Thrombosis and Haemostasis
[Georg Thieme Verlag KG]
日期:2010-01-01
卷期号:104 (08): 318-326
被引量:5
摘要
Summary Circulating endothelial cells (CEC) are considered a promising marker to determine the extent of vascular damage. However, currently available and validated CEC enumeration assays are laborious, time consuming and costly, which limits their clinical utility. Here, we evaluated the feasibility of quantifying mRNA levels of the endothelium-associated markers CD31, CD144, CD146 and von Willebrand factor (vWf) in peripheral blood (PB) of healthy donors, patients, and human umbilical veins by real-time reverse transcriptase polymerase chain reaction (RTPCR) and their use as surrogate markers for CEC. Whole blood samples and CD146+ cell-enriched fractions were assessed for mRNA and protein expression of CD31, CD144, CD146 and vWf by RT-PCR and flow cytometry, respectively. We showed the feasibility to detect endothelial mRNA isolated from HUVEC numbers as low as 10. However, no endothelial mRNA could be measure in whole blood samples, and only low levels of CD31 and CD146 mRNA were detected in suspensions of isolated CEC with numbers up to 4,450 CEC per sample. We conclude that mRNA levels of CD31, CD144, CD146 and vWf in whole blood as detected by real time RT-PCR cannot be used as biomarkers for endstage endothelial cells such as CEC.
科研通智能强力驱动
Strongly Powered by AbleSci AI